The GJB2 Gene Deafness Autosomal Recessive Type 1A Genetic Test is a specialized diagnostic procedure aimed at identifying mutations in the GJB2 gene, which are linked to Autosomal Recessive Non-Syndromic Sensorineural Deafness Type 1A (DFNB1A). This condition is characterized by a decrease in the ability to hear sounds, resulting from genetic variations that affect the normal function of the GJB2 gene, crucial for the development and maintenance of the inner ear structures responsible for sound transmission.
Conducted at DNA Labs UAE, this test is crucial for early diagnosis, enabling timely intervention and management strategies for individuals affected by this form of genetic hearing loss. It involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed for specific mutations in the GJB2 gene. The results can provide valuable information for affected families regarding the inheritance pattern, potential for recurrence in future offspring, and guide decision-making regarding genetic counseling.
The cost of the GJB2 Gene Deafness Autosomal Recessive Type 1A Genetic Test at DNA Labs UAE is 4400 AED. Given the complexity of genetic testing and the profound impact the results can have on individuals and families, it is often accompanied by pre- and post-test counseling to ensure that the implications of the test results are fully understood.
The GJB6 gene, also known as Gap Junction Beta 6, plays a crucial role in the development and function of the cochlea, the auditory portion of the inner ear. Mutations in this gene are associated with a form of non-syndromic hearing loss, specifically autosomal recessive deafness type 1B. This condition is characterized by the inheritance of two copies of the mutated gene, one from each parent, leading to a higher risk of developing hearing loss from birth or early childhood without affecting other body systems.
To diagnose this condition, a genetic test targeting the GJB6 gene can be conducted. This test involves analyzing the patient's DNA to identify mutations in the GJB6 gene that are known to cause deafness. The test is particularly useful for families with a history of hearing loss and can provide valuable information for early intervention and management strategies for affected individuals.
In the UAE, DNA Labs offers this specialized genetic test for identifying mutations in the GJB6 gene associated with autosomal recessive deafness type 1B. The cost of the test is set at 4400 AED. Conducting the test at DNA Labs UAE ensures that patients receive accurate and reliable results, thanks to the lab's state-of-the-art technology and expertise in genetic diagnostics. Early detection through this test can significantly impact the quality of life of individuals with hereditary deafness, allowing for timely interventions such as hearing aids, cochlear implants, or other supportive measures to enhance hearing and communication skills.
The EYA4 gene plays a critical role in the development of the auditory system, and mutations in this gene can lead to hearing loss. Autosomal Dominant Deafness Type 10, linked to the EYA4 gene, is a genetic condition characterized by progressive, sensorineural hearing loss. Individuals with this condition typically begin to experience hearing impairment in childhood or early adulthood, which can vary in severity.
To diagnose this specific type of hearing loss, a genetic test targeting the EYA4 gene can be conducted. This test is crucial for individuals with a family history of hearing loss or for those experiencing symptoms of hearing impairment without a clear cause. It involves analyzing the DNA to identify mutations in the EYA4 gene that are known to be associated with Autosomal Dominant Deafness Type 10.
In the UAE, DNA Labs offers this specialized genetic test. The cost of the test is 4400 AED, a price that reflects the comprehensive analysis and the specific expertise required to interpret the results accurately. Conducting the test at DNA Labs UAE ensures that individuals receive precise information about their genetic status concerning the EYA4 gene, facilitating informed decisions about management and treatment options for hearing loss. This test is an invaluable tool for affected families, providing them with the necessary insights to understand their condition better and potentially prevent further hearing deterioration through early intervention.
The MYO7A Gene Deafness Autosomal Dominant Type 11 Genetic Test is a specialized diagnostic assessment offered by DNA Labs UAE, aimed at identifying mutations in the MYO7A gene, which are linked to a form of autosomal dominant non-syndromic hearing loss. This condition, known as Autosomal Dominant Deafness Type 11, is characterized by varying degrees of hearing impairment that can affect individuals differently, even within the same family. The test is crucial for families with a history of hearing loss, as it can provide valuable insights into the genetic underpinnings of their condition, enabling informed decisions about management and treatment options. Conducted in a state-of-the-art laboratory setting, the test involves analyzing the patient's DNA sample to look for specific genetic alterations associated with this type of hearing loss. The cost of the MYO7A Gene Deafness Autosomal Dominant Type 11 Genetic Test at DNA Labs UAE is 4400 AED, reflecting the advanced technology and expertise required to accurately identify the presence of MYO7A gene mutations.
The TECTA Gene Deafness Autosomal Dominant Type 12 Genetic Test is a specialized diagnostic tool used to identify mutations in the TECTA gene, which can lead to autosomal dominant non-syndromic hearing loss, specifically categorized as type 12. This form of hearing loss is characterized by its genetic inheritance pattern, where a single copy of the altered gene in each cell is sufficient to cause the condition. The TECTA gene is crucial for the proper development and function of the inner ear, which plays a significant role in the ability to hear.
Conducted at DNA Labs UAE, this genetic test is designed to provide individuals and families with crucial information regarding the genetic basis of their hearing loss, facilitating early diagnosis and intervention strategies. With a cost of 4400 AED, the test is a valuable resource for those with a family history of hearing loss or for individuals experiencing hearing difficulties, aiming to understand the genetic underpinnings of their condition. By identifying specific mutations in the TECTA gene, healthcare providers can offer more personalized management plans and genetic counseling, helping affected individuals and their families navigate the challenges associated with hearing loss.
The COL11A2 gene plays a crucial role in the production of a specific type of collagen, which is essential for the proper development and maintenance of structures within the ear. Mutations in the COL11A2 gene are associated with autosomal dominant non-syndromic hearing loss, specifically categorized as Deafness, Autosomal Dominant Type 13 (DFNA13). This condition is characterized by the progressive loss of hearing, which typically begins in childhood or early adulthood.
To diagnose this specific genetic cause of hearing loss, DNA Labs UAE offers a genetic test that targets the COL11A2 gene. This test is designed to identify mutations within the gene that are known to result in DFNA13. It is a crucial tool for families with a history of hearing loss, as it can provide a definitive diagnosis, guide treatment decisions, and inform family planning.
The test is priced at 4400 AED and involves collecting a DNA sample, usually through a blood draw or a cheek swab. The sample is then analyzed in the laboratory for the presence of mutations in the COL11A2 gene. Results from the test can help in understanding the genetic basis of hearing loss in affected individuals and facilitate genetic counseling for the family. It is important for potential patients to consult with a healthcare provider or a genetic counselor before and after undergoing genetic testing to fully understand the implications of the test results.
The POU4F3 gene is associated with Autosomal Dominant Deafness Type 15 (DFNA15), a genetic condition that affects hearing. The POU4F3 gene plays a crucial role in the development and maintenance of hair cells in the inner ear, which are essential for normal hearing. Mutations in the POU4F3 gene can lead to progressive hearing loss, typically starting in late childhood or early adulthood.
To diagnose this specific type of genetic deafness, DNA Labs UAE offers a genetic test targeting the POU4F3 gene. This test is designed to identify mutations in the POU4F3 gene that are responsible for Autosomal Dominant Deafness Type 15. Early identification of these mutations can be beneficial for affected individuals and their families for several reasons, including understanding the cause of the hearing loss, exploring potential treatment options, and making informed decisions about family planning.
The cost of the POU4F3 Gene Deafness Autosomal Dominant Type 15 Genetic Test at DNA Labs UAE is 4400 AED. This investment includes the collection of a DNA sample, usually through a blood draw or cheek swab, and comprehensive analysis to detect any mutations in the POU4F3 gene. Results from this test can provide valuable information for managing and treating hearing loss associated with DFNA15.
The MYH9 Gene Deafness Autosomal Dominant Type 17 Genetic Test is a specialized diagnostic tool designed to identify mutations in the MYH9 gene, which are linked to a specific form of hearing loss known as Autosomal Dominant Nonsyndromic Deafness Type 17 (DFNA17). This condition is characterized by its inheritance pattern, where only one copy of the mutated gene, inherited from an affected parent, is sufficient to cause the disorder. The MYH9 gene plays a crucial role in the development and function of the inner ear structures, which are essential for normal hearing.
Conducted at DNA Labs UAE, this genetic test involves analyzing the patient's DNA, extracted from a blood sample, to search for mutations in the MYH9 gene. The process is highly sophisticated and requires advanced laboratory techniques to accurately identify the genetic alteration responsible for the hearing impairment.
The cost of the MYH9 Gene Deafness Autosomal Dominant Type 17 Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the intricate nature of the testing process and the specialized expertise required to interpret the results. Patients undergoing this test can expect a comprehensive analysis that will not only aid in confirming a diagnosis of DFNA17 but also provide essential information for family planning and management of the condition. The test is a critical step for affected families in understanding their genetic makeup and assessing the risk of passing the condition on to future generations.
The ACTG1 gene, associated with Autosomal Dominant Deafness Type 20 (DFNA20), plays a crucial role in the function and structure of inner ear cells, which are essential for hearing. Mutations in the ACTG1 gene can lead to hearing impairment, typically characterized by progressive, sensorineural hearing loss. This condition is inherited in an autosomal dominant pattern, meaning that a mutation in just one of the two copies of the gene in each cell is sufficient to cause the disorder.
To diagnose this specific type of genetic hearing loss, a genetic test targeting the ACTG1 gene can be conducted. DNA Labs UAE offers such a test, providing a comprehensive analysis to detect mutations in the ACTG1 gene that are responsible for Autosomal Dominant Deafness Type 20. The test is crucial for individuals with a family history of hearing loss or those experiencing symptoms of hearing impairment, as it can confirm the diagnosis, guide management and treatment decisions, and inform family planning.
The cost of the ACTG1 Gene Deafness Autosomal Dominant Type 20 Genetic Test at DNA Labs UAE is 4400 AED. The test is conducted in a state-of-the-art laboratory setting by experienced geneticists and technicians, ensuring accurate and reliable results. The process involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed for the presence of mutations in the ACTG1 gene.
By opting for this genetic test, individuals and families can gain valuable insights into the genetic basis of hearing loss, enabling informed decisions regarding healthcare and lifestyle adjustments to better manage the condition.
The MYO6 Gene Deafness Autosomal Dominant Type 22 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the MYO6 gene, which are associated with Autosomal Dominant Non-Syndromic Sensorineural Hearing Loss (ADNSHL) Type 22. This condition is characterized by varying degrees of hearing impairment that can present from birth or develop later in life, affecting individuals and families across generations due to its autosomal dominant inheritance pattern.
The test is crucial for families with a history of hearing loss, as it provides essential information for understanding the genetic basis of their condition. Early detection through genetic testing can facilitate timely interventions and support, including hearing aids, cochlear implants, or other therapeutic approaches tailored to the individual's needs. Additionally, it offers valuable insights for family planning and the assessment of risk in future generations.
Performed in the state-of-the-art facilities of DNA Labs UAE, the test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed for specific mutations in the MYO6 gene. The cost of the test is 4400 AED, reflecting the comprehensive analysis and personalized consultation provided to discuss the results and their implications for the patient and their family.
